Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by HB Wealth Management LLC

HB Wealth Management LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 46.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,411 shares of the biopharmaceutical company's stock after buying an additional 8,406 shares during the period. HB Wealth Management LLC's holdings in Gilead Sciences were worth $2,440,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of GILD. nVerses Capital LLC bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $25,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth $29,000. Valued Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth $33,000. Finally, Friedenthal Financial purchased a new position in Gilead Sciences during the 3rd quarter worth $50,000. Institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Truist Financial lifted their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research note on Friday, November 8th. Morgan Stanley raised shares of Gilead Sciences from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Mizuho boosted their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group raised their target price on Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a research note on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $97.96.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded up $0.19 on Monday, hitting $91.84. The company's stock had a trading volume of 6,852,085 shares, compared to its average volume of 5,370,915. The company has a market capitalization of $114.46 billion, a price-to-earnings ratio of 1,020.44, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18. The firm has a fifty day moving average price of $91.75 and a 200-day moving average price of $84.20. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the company posted $2.29 EPS. The business's quarterly revenue was up 7.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.35%. Gilead Sciences's dividend payout ratio is currently 3,422.22%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. The trade was a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 in the last 90 days. Insiders own 0.29% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.